BALTIMORE--(BUSINESS WIRE) 6 August 2025 11:00 AM -- Pearl Diagnostics proudly announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the MycoMEIA® Aspergillus Assay –…

BALTIMORE  – June 17, 2025 – Pearl Diagnostics, a Johns Hopkins University spin-off specializing in non-invasive diagnostics for lung infections, announced today it has received a strategic investment from the…

BOSTON -  February 11, 2025 – Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award biotechnology company Pearl Diagnostics US$1M to develop a low-cost, low turnaround time urine assay for the…

Pearl Diagnostics develops tests to diagnose the critical fungal infections the WHO highlighted on Tuesday. As we work with partners including GAFFI-The Global Action Fund for Fungal Infections and scientific…

Dr. Kieren Marr retired from a faculty position at Johns Hopkins University at the beginning of this year because she knew the impact Pearl Diagnostics would have on diagnosing fungal…

In April 2018, Pearl Diagnostics published a paper in Clinical Infectious Diseases titled: “Urine Antigen Detection as an Aid to Diagnose Invasive Aspergillosis”. Pearl Diagnostics in collaboration with Johns Hopkins University…